Evidence map›Paper›PMID 30275285›Full record

ArticleDiabetes care2018

Transcription Factor 7-Like 2 (

Maria J Redondo, Andrea K Steck, Jay Sosenko, Mark Anderson, Peter Antinozzi, Aaron Michels, John M Wentworth, Mark A Atkinson, Alberto Pugliese, Susan Geyer and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Time to reframe the disease staging system for type 1 diabetes.The lancet. Diabetes & endocrinology · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Article
  19. Article
  20. Birth and coming of age of islet autoantibodies.Clinical and experimental immunology · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Maria J RedondoBaylor College of Medicine, Texas Children's Hospital, Houston, TX redondo@bcm.edu.ORCID 0000-0001-5871-4645
Andrea K SteckBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0002-5931-9484
Jay SosenkoUniversity of Miami, Miami, FL.ORCID 0000-0002-7204-8367
Mark AndersonUniversity of California San Francisco, San Francisco, CA.
Peter AntinozziWake Forest School of Medicine, Winston-Salem, NC.
Aaron MichelsBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0003-3766-5244
John M WentworthWalter and Eliza Hall Institute and Royal Melbourne Hospital, Parkville, Australia.ORCID 0000-0002-5197-3529
Mark A AtkinsonUniversity of Florida, Gainesville, FL.
Alberto PuglieseUniversity of Miami, Miami, FL.
Susan GeyerUniversity of South Florida, Tampa, FL.
Type 1 Diabetes TrialNet Study Group
University of Colorado Denver · USUniversity of Miami · USBaylor College of Medicine · USThe Royal Melbourne Hospital · AUUniversity of California, San Francisco · USUniversity of Florida · USUniversity of South Florida · USWake Forest University · US

Funding

Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3UC4DK117009 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2017 to 2019
$49.6M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
NIDDK Type 1 Diabetes TrialNet Data Coordinating CenterUC4DK106993 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2015 to 2015
$36.6M
Type 1 Diabetes TrialNet Clinical Network HubU01DK103282 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI CARLA J GREENBAUM, KURT J GRIFFIN · 2014 to 2026
$14.2M
Northwest Clinical Center for Type 1 Diabetes - TrialNetU01DK061034 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI GREENBAUM, CARLA J · 2001 to 2018
$10.3M
Type I Diabetes Trialnet at StsnfordU01DK061042 · NIDDK · STANFORD UNIVERSITY · PI WILSON, DARRELL M · 2001 to 2018
$8.5M
UCSF Trialnet: A Phase II Trial of Imatimib in New Onset Type I DiabetesU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GITELMAN, STEPHEN E · 2001 to 2018
$8.1M
Type 1 Diabetes-A Proposal for Prevention & InterventionU01DK085476 · NIDDK · UNIVERSITY OF MINNESOTA · PI MORAN, ANTOINETTE M. · 2009 to 2018
$7.1M
Prediction and Prevention of Type I DiabetesU01DK061058 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, DOROTHY J · 2001 to 2018
$6.5M
TrialNet: University of Florida Clinical Center and NetworkU01DK085461 · NIDDK · UNIVERSITY OF FLORIDA · PI HALLER, MICHAEL JAMES · 2009 to 2018
$5.9M
TrialNet: Diabetes Type 1 PreventionU01DK085509 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GOTTLIEB, PETER A · 2009 to 2018
$5.8M
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1DU01DK085499 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BAIDAL, DAVID · 2009 to 2018
$4.9M
NIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK108868NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK061034NIDDK NIH HHS U01 DK061042NIDDK NIH HHS U01 DK061058NIDDK NIH HHS U01 DK085453NIDDK NIH HHS U01 DK085461NIDDK NIH HHS U01 DK085465NIDDK NIH HHS U01 DK085466NIDDK NIH HHS U01 DK085476NIDDK NIH HHS U01 DK085499NIDDK NIH HHS U01 DK085504NIDDK NIH HHS U01 DK085509NIDDK NIH HHS U01 DK103153NIDDK NIH HHS U01 DK103180NIDDK NIH HHS U01 DK103266NIDDK NIH HHS U01 DK103282NIDDK NIH HHS U01 DK106984NIDDK NIH HHS U01 DK106994NIDDK NIH HHS U01 DK107013NIDDK NIH HHS U01 DK107014NIDDK NIH HHS UC4 DK106993NIDDK NIH HHS UC4 DK117009
6 · The paper itself

Abstract

objectiveThe type 2 diabetes-associated alleles at the RESEARCH DESIGN AND

methodsWe evaluated 244 participants in the Type 1 Diabetes TrialNet Pathway to Prevention study with confirmed single autoantibody positivity at screening and Immunochip single nucleotide polymorphism data (47.5% male; median age 12.8 years, range 1.2-45.9; 90.2% white). We analyzed risk allele frequency at

resultsDuring follow-up (median 5.2 years, range 0.2-12.6), 62% of the single autoantibody-positive participants developed multiple autoantibody positivity. In the overall cohort, the

conclusionsThe type 2 diabetes-associated

Indexed as

Polymorphism, Single NucleotideAdolescentAdultAntibody SpecificityAutoantibodiesAutoimmunityChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Disease ProgressionFemaleGene FrequencyGenetic Predisposition to DiseaseHumansInfantAutoantibodiesTCF7L2 protein, humanTranscription Factor 7-Like 2 Protein

Identifiers

PMID30275285
PMCPMC6245213
OpenAlexW2894569768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.